{"id":29785,"date":"2012-08-08T07:57:34","date_gmt":"2012-08-08T07:57:34","guid":{"rendered":"http:\/\/countingpips.com\/fx\/?p=29785"},"modified":"2012-08-08T07:57:35","modified_gmt":"2012-08-08T07:57:35","slug":"video-cvs-beats-second-quarter-earnings-estimates-raises-full-year-outlook","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/fx\/2012\/08\/08\/video-cvs-beats-second-quarter-earnings-estimates-raises-full-year-outlook\/","title":{"rendered":"VIDEO: CVS Beats Second Quarter Earnings Estimates, Raises Full Year Outlook"},"content":{"rendered":"<p><div id=\"grabDiv1767162\"><object id=\"GrabPlayer1767162\" width=\"542\" height=\"304\" type=\"application\/x-shockwave-flash\" align=\"middle\" data=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v55587e8c97cac395a4cafd7707de515711f52a30&#038;tgt=grabnetworks\"><param name=\"quality\" value=\"high\"\/><param name=\"allowScriptAccess\" value=\"always\"\/><param name=\"allowFullScreen\" value=\"true\"\/><param name=\"menu\" value=\"false\"\/><param name=\"wmode\" value=\"transparent\"\/><param name=\"movie\" value=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v55587e8c97cac395a4cafd7707de515711f52a30&#038;tgt=grabnetworks\"\/><\/object><\/p>\n<div id=\"overlay-adzone\" style=\"overflow:hidden; position:relative\"><\/div>\n<\/div>\n<p>CVS Caremark (NYSE:CVS) reporting their second quarter earnings this morning, posting an EPS of 81 cents, higher than the 80 cents analysts were expecting. Revenue also rose 16.3% to $30.71 billion, but just came below analyst estimates of $30.98 billion. The company said the rise in earnings was due to a contract dispute between Walgreens and Express Scripts. CVS&#8217;s main competitor stopped filling prescriptions for Express Scripts patients at the beginning of 2012, allowing CVS to gain some more customers. However, the dispute has been settled and Walgreens will start filling prescriptions again on September 15. CVS also raised its full year forecast on EPS, saying it expects $3.32 to $3.38 a share for the fiscal year. Analysts are expecting earnings to be $3.33.<\/p>\n<p><img src='http:\/\/images.grab-media.com\/financial_news_network\/2012\/08\/08\/1_p260rh5r_thumb.jpg' \/><\/p>\n<p><!--post_img[http:\/\/images.grab-media.com\/financial_news_network\/2012\/08\/08\/1_p260rh5r_preview.jpg]--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CVS Caremark (NYSE:CVS) reporting their second quarter earnings this morning, posting an EPS of 81 cents, higher than the 80 cents analysts were expecting. Revenue also rose 16.3% to $30.71 billion, but just came below analyst estimates of $30.98 billion. The company said the rise in earnings was due to a contract dispute between Walgreens &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.investmacro.com\/fx\/2012\/08\/08\/video-cvs-beats-second-quarter-earnings-estimates-raises-full-year-outlook\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;VIDEO: CVS Beats Second Quarter Earnings Estimates, Raises Full Year Outlook&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-29785","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/29785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/comments?post=29785"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/29785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/media?parent=29785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/categories?post=29785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/tags?post=29785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}